Full Press Release Details
Alpha Tau to Participate
in Citi's 2023 Healthcare
Services, Medtech, Tools & HCIT Conference
February 21, 2023 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the "Company"), the developer
of the innovative alpha-radiation cancer therapy Alpha DaRT , announced today that the Company plans
to participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023 taking place at Citi HQ
Conference Center in New York City.
2023 Healthcare Services, Medtech, Tools & HCIT Conference:
Wednesday, March 1, 2023
Citi HQ Conference Center
you would like to schedule a 1:1 meeting, please contact your Citi representative.
DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors
by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources
and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse
only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha Tau Medical Ltd.
in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the
Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from
Tel Aviv University.